-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
With the continuous advancement of consistency evaluation and centralized procurement policies, China's pharmaceutical industry has begun to accelerate into an accelerated period of transformation and upgrading
.
It is worth noting that in order to meet the growing demand for clinical services and improve production capacity and service efficiency, many pharmaceutical companies are currently expanding production by using new technologies and new projects to prepare for improving market competitiveness
.
Recently, Jiangxi Xinglin Baima Pharmaceutical Co.
, Ltd.
(referred to as "White Horse Pharmaceutical") has updated its prospectus and intends to sprint to the Growth Enterprise Market.
Center construction project and marketing network construction project
.
Baima Pharmaceutical said that the current domestic epidemic has been basically under control.
Based on the forecast of future market demand growth, the current situation of relatively saturated production and sales scale, and the limitations of the production efficiency of existing production equipment, the company plans to pass this fundraising project.
The implementation of this will further improve production efficiency and capacity scale, ease the current situation of tight production capacity, improve supply efficiency, and meet the growing market demand in the future
.
In fact, with the continuous advancement of policies such as the normalization of centralized drug procurement and medical insurance, the expansion of production capacity of pharmaceutical companies has become normal under the background that innovation and transformation have become the consensus of industry development
.
Since the beginning of this year, there have been reports of actions by pharmaceutical companies to expand production capacity
.
For example, on August 18, Boton announced that it plans to acquire 70% of Yuyang Pharmaceutical for 171.
5 million yuan
.
After the completion of the transaction, Proton will have 3 chemical raw material drug CDMO production bases in Chongqing Changshou, Jiangxi Yichun and Hubei Yingcheng, and the production capacity will be further expanded to 2000m³
.
On June 7, Hongri Pharmaceuticals held a groundbreaking ceremony for the intelligent manufacturing base of Chinese medicine formula granules with an investment of 750 million yuan, covering an area of 100 acres, and extracting 10,000 tons of Chinese medicinal materials per year in Shanghe County, Jinan City, Shandong Province
.
It is understood that after the Shandong base is completed, Hongri Pharmaceutical will produce 3,000 tons of traditional Chinese medicine formula granules annually, with an annual sales scale of about 3 billion yuan
.
This will not only enrich and improve the company's national production capacity layout of Chinese medicine formula granules, but also provide a strong guarantee for the company's main business to continue to grow
.
On May 10, Guoxin Tianjiang Pharmaceutical's production and processing base of Chinese medicine decoction pieces and formula granules was put into operation
.
The first phase of the project has been completed, with an investment of more than 500 million yuan, a construction area of 70,000 square meters, and a designed production capacity of 5,000 tons/year of processed decoction pieces and 3,000 tons/year of traditional Chinese medicine formula granules.
The production scale and production capacity are among the top in North China.
.
It is reported that the project is expected to produce 1,049 tons of various traditional Chinese medicine decoction pieces and formula granules in the year when the project is put into operation, with an output value of 238 million yuan
.
In general, the expansion of production capacity of pharmaceutical companies is to advance the clinical pipeline on the one hand, and on the other hand, it is also based on commercial considerations.
As domestic new drugs continue to enter the clinical research and development stage, companies who want to stand out will be even more inseparable from scale.
Production
.
Therefore, judging from the current industry development trend, the industry expects that capacity expansion will become the norm in the industry, and development will accelerate in the context of enterprise technological innovation and industrial upgrading
.
.
It is worth noting that in order to meet the growing demand for clinical services and improve production capacity and service efficiency, many pharmaceutical companies are currently expanding production by using new technologies and new projects to prepare for improving market competitiveness
.
Recently, Jiangxi Xinglin Baima Pharmaceutical Co.
, Ltd.
(referred to as "White Horse Pharmaceutical") has updated its prospectus and intends to sprint to the Growth Enterprise Market.
Center construction project and marketing network construction project
.
Baima Pharmaceutical said that the current domestic epidemic has been basically under control.
Based on the forecast of future market demand growth, the current situation of relatively saturated production and sales scale, and the limitations of the production efficiency of existing production equipment, the company plans to pass this fundraising project.
The implementation of this will further improve production efficiency and capacity scale, ease the current situation of tight production capacity, improve supply efficiency, and meet the growing market demand in the future
.
In fact, with the continuous advancement of policies such as the normalization of centralized drug procurement and medical insurance, the expansion of production capacity of pharmaceutical companies has become normal under the background that innovation and transformation have become the consensus of industry development
.
Since the beginning of this year, there have been reports of actions by pharmaceutical companies to expand production capacity
.
For example, on August 18, Boton announced that it plans to acquire 70% of Yuyang Pharmaceutical for 171.
5 million yuan
.
After the completion of the transaction, Proton will have 3 chemical raw material drug CDMO production bases in Chongqing Changshou, Jiangxi Yichun and Hubei Yingcheng, and the production capacity will be further expanded to 2000m³
.
On June 7, Hongri Pharmaceuticals held a groundbreaking ceremony for the intelligent manufacturing base of Chinese medicine formula granules with an investment of 750 million yuan, covering an area of 100 acres, and extracting 10,000 tons of Chinese medicinal materials per year in Shanghe County, Jinan City, Shandong Province
.
It is understood that after the Shandong base is completed, Hongri Pharmaceutical will produce 3,000 tons of traditional Chinese medicine formula granules annually, with an annual sales scale of about 3 billion yuan
.
This will not only enrich and improve the company's national production capacity layout of Chinese medicine formula granules, but also provide a strong guarantee for the company's main business to continue to grow
.
On May 10, Guoxin Tianjiang Pharmaceutical's production and processing base of Chinese medicine decoction pieces and formula granules was put into operation
.
The first phase of the project has been completed, with an investment of more than 500 million yuan, a construction area of 70,000 square meters, and a designed production capacity of 5,000 tons/year of processed decoction pieces and 3,000 tons/year of traditional Chinese medicine formula granules.
The production scale and production capacity are among the top in North China.
.
It is reported that the project is expected to produce 1,049 tons of various traditional Chinese medicine decoction pieces and formula granules in the year when the project is put into operation, with an output value of 238 million yuan
.
In general, the expansion of production capacity of pharmaceutical companies is to advance the clinical pipeline on the one hand, and on the other hand, it is also based on commercial considerations.
As domestic new drugs continue to enter the clinical research and development stage, companies who want to stand out will be even more inseparable from scale.
Production
.
Therefore, judging from the current industry development trend, the industry expects that capacity expansion will become the norm in the industry, and development will accelerate in the context of enterprise technological innovation and industrial upgrading
.
